Paraoxonase 1 Q192R variant and clopidogrel efficacy: fact or fiction?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The role ofExpert review of clinical pharmacology · 2022
   Pooled it
2. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.Cardiovascular diagnosis and therapy · 2018
   Review
3. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Cardiology research and practice · 2017
   Review
4. Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.International journal of clinical and experimental medicine · 2015
   Article
5. Pharmacogenomics of anti-platelet and anti-coagulation therapy.Current cardiology reports · 2013
   Review
6. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Journal of human genetics · 2013
   Review
7. A review of pharmacogenetics of adverse drug reactions in elderly people.Drug safety · 2012
   Review

Corrections and comments

• Comment on
  Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.2012

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as